Api pharmaceutical enterprises blindly expand production, revise relevant laws and regulations to promote transformation and upgrading

, according to the latest data obtained by reporters at the 2014 Pharmaceutical Fair, the pharmaceutical industry since the "12th Five-Year Plan" of the main economic indicators have grown rapidly, in which industrial value added has always maintained a relatively fast growth rate, in 2011 growth rate of 17.8%, in 2013 reached 12.7%, higher than the national industrial average of 3 percentage pointsIn addition, from 2011 to 2012, the relative compound growth rate of the first two years of the 12th Five-Year Plan was 23.1%In 2013, enterprises above the scale achieved main business revenue of RMB216.816 billion, up 17.9% YoYIn other words, main revenue scored more than $2 trillion, but growth was below 20 percent for the first time in yearsngVIn the "12th Five-Year Plan" implementation of the middle and late, the pharmaceutical industry's development goals specifically completed? What changes will appear in the macro-policy direction? In response to these questions, the Ministry of Industry and Information Technology at the drug fair site one by one gave the answerngVMerger and reorganization active duplication of construction seriousNGVministry of Industry and Information Technology Consumer Products Department of the Pharmaceutical Department official Wang Xueqian in the 2014 pharmaceutical fair assessment, with the "12th Five-Year Plan" pharmaceutical industry planning, in the main economic indicators of the data reflected, industrial value-added growth rate, main business income, etchave varying degrees of growth, and pharmaceutical mergers and reorganization active, according to incomplete statistics, 2011 to 2013 mergers and acquisitions of 500 yuan"A number of powerful enterprises through the implementation of overseas mergers and acquisitions, to build a platform to enter the international market, since the 12th Five-Year Plan, there have been dozens of overseas mergers and acquisitions"
NGVbut Wang Xueqian said that according to the Ministry of Industry and Information Technology, in January and February of this year, the total profit of the pharmaceutical manufacturing industry increased by 13.8% Year-on-year, compared with last year's average decline, the worst performance is the chemical API industry or chemical raw materials-based enterprises, compound growth rate of only 16.8%, profit only 6.3%, indicating that the level of profit in the sub-sectors is decliningngVSpecifically, the "12th Five-Year Plan" in the first half of the implementation of the problems exposed, first reflected in the API, that is, low-level repeated construction serious, and blind expansion, some bulk API capacity utilization rate of only 50% to 70%The slow reduction of production capacity by weakly competitive enterprises has exacerbated the contradiction between supply and demand, leading to excessive competition, waste of resources, environmental pollution and depressed pricesngVTaking genericdrugs as an example, there is a phenomenon of duplicate declaration, in 2012 the State Food and Drug Administration (SFDA) accepted 2095 chemical generic drugs, there are more than 20 approved drugs still have 1272 applicationsRepeated declaration for the product homogenization competition buried hidden dangers, industrial concentration has not been effectively improvedThe share of sales revenue fell from 33.4 per cent in 2010 to 18.4 per cent in 2012ngVAt the same time, falling prices affect industry earningsProfit growth averaged 18.9% from 2010 to 2012, reflecting a decline in industry earningsThe main reasons for the decline in prices are, first, bidding, especially since the 12th Five-Year Plan, which has led to a significant decline in drug prices;ngVFrom the macro level, the innovation incentive policy in the middle and late part of the 12th Five-Year Plan needs to be perfectedngVWith the increase of new drug research and development enterprises, new drug market access is facing a long product registration cycle, difficult to enter the medical insurance and other issues are increasingly prominent, coupled with the new drug creation itself investment, risk, affecting the enthusiasm of enterprise innovationInnovative medical devices face the same problemngV"However, we feel that the pharmaceutical industry is still maintaining rapid growth, especially in various industrial categories than, the next Ministry of Industry and Information Technology will do industry operation analysis," Wang said "
NGV regulations revision in that pharmaceutical enterprises must transform
API enterprises blindly expand production Revision of relevant regulations to promote transformation and upgrading
apite enterprises blindly expand production revision of relevant regulations (2) 1 / 2 1 2 the next days, according to Reporters at the 2014 Pharmaceutical Fair obtained the latest data, the pharmaceutical industry since the "12th Five-Year Plan" of rapid growth of the main economic indicators, in which industrial value added has always maintained a relatively fast growth rate, in 2011 growth rate of 17.8%, in 2013 reached 12.7%, higher than the national industrial average of 3 percentage points In addition, from 2011 to 2012, the relative compound growth rate of the first two years of the 12th Five-Year Plan was 23.1% In 2013, enterprises above the scale achieved main business revenue of RMB216.816 billion, up 17.9% YoY In other words, main revenue scored more than $2 trillion, but growth was below 20 percent for the first time in years ngV 　　In the "12th Five-Year Plan" implementation of the middle and late, the pharmaceutical industry's development goals specifically completed? What changes will appear in the macro-policy direction? In response to these questions, the Ministry of Industry and Information Technology at the drug fair site one by one gave the answer ngV 　　Merger and reorganization active duplication of construction serious NGV ministry of Industry and Information Technology Consumer Products Department of the Pharmaceutical Department official Wang Xueqian in the 2014 pharmaceutical fair assessment, with the "12th Five-Year Plan" pharmaceutical industry planning, in the main economic indicators of the data reflected, industrial value-added growth rate, main business income, etc have varying degrees of growth, and pharmaceutical mergers and reorganization active, according to incomplete statistics, 2011 to 2013 mergers and acquisitions of 500 yuan "A number of powerful enterprises through the implementation of overseas mergers and acquisitions, to build a platform to enter the international market, since the 12th Five-Year Plan, there have been dozens of overseas mergers and acquisitions "
NGV but Wang Xueqian said that according to the Ministry of Industry and Information Technology, in January and February of this year, the total profit of the pharmaceutical manufacturing industry increased by 13.8% Year-on-year, compared with last year's average decline, the worst performance is the chemical API industry or chemical raw materials-based enterprises, compound growth rate of only 16.8%, profit only 6.3%, indicating that the level of profit in the sub-sectors is declining ngV 　　Specifically, the "12th Five-Year Plan" in the first half of the implementation of the problems exposed, first reflected in the API, that is, low-level repeated construction serious, and blind expansion, some bulk API capacity utilization rate of only 50% to 70% The slow reduction of production capacity by weakly competitive enterprises has exacerbated the contradiction between supply and demand, leading to excessive competition, waste of resources, environmental pollution and depressed prices ngV 　　Taking genericdrugs as an example, there is a phenomenon of duplicate declaration, in 2012 the State Food and Drug Administration (SFDA) accepted 2095 chemical generic drugs, there are more than 20 approved drugs still have 1272 applications Repeated declaration for the product homogenization competition buried hidden dangers, industrial concentration has not been effectively improved The share of sales revenue fell from 33.4 per cent in 2010 to 18.4 per cent in 2012 ngV 　　At the same time, falling prices affect industry earnings Profit growth averaged 18.9% from 2010 to 2012, reflecting a decline in industry earnings The main reasons for the decline in prices are, first, bidding, especially since the 12th Five-Year Plan, which has led to a significant decline in drug prices; ngV 　　From the macro level, the innovation incentive policy in the middle and late part of the 12th Five-Year Plan needs to be perfected ngV 　　With the increase of new drug research and development enterprises, new drug market access is facing a long product registration cycle, difficult to enter the medical insurance and other issues are increasingly prominent, coupled with the new drug creation itself investment, risk, affecting the enthusiasm of enterprise innovation Innovative medical devices face the same problem ngV 　　"However, we feel that the pharmaceutical industry is still maintaining rapid growth, especially in various industrial categories than, the next Ministry of Industry and Information Technology will do industry operation analysis," Wang said "
NGV regulations are revised in that pharmaceutical companies must be transformed